Published in Vaccine Weekly, August 16th, 2006
According to scientists writing in the Journal of Urology, "Men with biochemical failure after radical prostatectomy have few therapeutic options other than androgen deprivation therapy. Targeted therapies in this group are appropriate because the optimal timing of the initiation of hormonal therapy in this patient population is unknown."
Scott A. North and colleagues at Biomira, Inc. wrote, "A single institution pilot trial was performed using BLP25 liposome vaccine in hormone-naive patients with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly